GERN obtained a worldwide, exclusive license to Angiochem‘s peptide technology, which is expected to help anticancer agents move across the blood-brain barrier (BBB). Read more…
GERN announced the pricing of an underwritten public offering of 17,391,305 shares of its common stock at a price to the public of $5.00 per share. Read more…
Telomerase is a critical and broadly applicable tumor target. Read more…
GERN published (11/11/10) preclinical data demonstrating that its telomerase inhibitor drug, imetelstat (GRN163L) targets cancer stem cells Read more…
Q3/10 reported a net loss applicable to common stockholders of $18.3M or $(0.19) per share. Read more…
GERN enrolled the 1st patient in the clinical trial of human embryonic stem cell (hESC)-derived oligodendrocyte progenitor cells, GRNOPC1. Read more…
Geron/GE Healthcare has launched (10/5/10) the co-developed human cellular assay product human cardiomyocytes (heart muscle cells) Read more…
The patenting of human embryonic stem (hES) cells could produce yet another ambiguous controversy concerning science, ethics and legal issues related to stem cell … intellectual property (IP). Read more…
GERN announced that it has entered into a worldwide, exclusive license agreement with the University of Edinburgh, UK covering technology that allows the efficient production of chondrocytes (cartilage forming cells) from human pluripotent stem cells. Read more…
The stem cell stocks index was up 2% on 9/9/10 post the Circuit Court appeals process with many gaining … and some losing: Read more…
Founder and Director of Research, Henry McCusker enters his eighth (8) year at Scimitar Equity with past experience in sell-side analysis, buy-side management, corporate management and due diligence.